Glassy cell carcinoma of the uterine cervix: combination chemotherapy with paclitaxel and carboplatin in recurrent tumor.
Combination chemotherapy with paclitaxel and carboplatin every 4 weeks for 3 cycles was administered for recurrent glassy cell carcinoma of the uterine cervix in a 67-year-old Japanese female. The response rate was 56% under computed tomography (partial response). However, the effect was transient even with follow-up radiotherapy, and further cases need to be accumulated to determine a successful treatment modality.
Matsuura
Y
Y
Department of Obstetrics and Gynecology, University of Occupational and Environmental Health, Kyushu, Japan.
Murakami
N
N
Nagashio
E
E
Toki
N
N
Kashimura
M
M
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D002466:Cell Nucleolus / Q000473:pathology; D002467:Cell Nucleus / Q000473:pathology; D003131:Combined Modality Therapy; D003593:Cytoplasm / Q000473:pathology; D005187:Fallopian Tubes / Q000601:surgery; D005260:Female; D006801:Humans; D007044:Hysterectomy; D008197:Lymph Node Excision; D008279:Magnetic Resonance Imaging; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D010052:Ovariectomy; D017239:Paclitaxel / Q000627:therapeutic use; D011878:Radiotherapy; D014057:Tomography, X-Ray Computed; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*
D016190:Carboplatin; D017239:Paclitaxel